Rialto South Tower
Level 23 525 Collins Street
Melbourne, VIC 3000
Australia
61 2 9698 5414
https://www.algoraepharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. David Richard Hainsworth | CEO & Executive Chairman | 26,44k | S.O. | 1974 |
Mr. Daya Uka B.Com., C.A. | Chief Financial Officer | 101,19k | S.O. | S.O. |
Dr. Belinda Di Bartolo | Chief Operations Officer | 120,52k | S.O. | S.O. |
Dr. Carolyn M. Sue A.M., B.S., Ph.D. | Member of Medical Advisory Board & Chief Medical Officer of NTCELL | 33,05k | S.O. | 1963 |
Dr. James A. Mckenna | Chief Scientific Officer | S.O. | S.O. | S.O. |
Ms. Leah Pieris | Company Secretary | S.O. | S.O. | S.O. |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
L’ISS Governance QualityScore de Algorae Pharmaceuticals Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..